Lundbeckfonden BioCapital
Lundbeckfonden BioCapital is the direct biotech venture investment arm of the Lundbeck Foundation (Lundbeckfonden), a Copenhagen-based Danish commercial foundation. It is an evergreen life-science venture capital investor that backs therapeutics and drug-development companies across all disease areas and stages, from inception to clinical validation, frequently as lead or co-lead in Series A and B rounds, with a strong focus on building the Danish biotech ecosystem. The BioCapital unit was formed in 2022 by merging the foundation's two prior direct-investment teams, Lundbeckfonden Ventures (established autumn 2009, international life science) and Lundbeckfonden Emerge (established 2012, early-stage Danish), and it invests off the foundation's balance sheet rather than from a closed-end fund. Lundbeck Foundation reported the combined portfolio held more than DKK 2 billion across about 20 companies in 2022 and set an ambition to expand the BioCapital investment framework to DKK 4 billion by 2030.
Lundbeckfonden BioCapital is a Copenhagen venture capital firm with 14 active companies and 4 exits.
- ·4 exits in the last 5 years · consistent DPI cadence.
- ·Average hold across 4 realized deals: 4 years.
- ·Top sector focus: Biotech (89% of portfolio).
Sector breakdown
18 companiesGeography breakdown
5 geographiesKey facts
Recent exits
Lundbeckfonden BioCapital took Lexeo Therapeutics public in 2023 after 2 years.
Lundbeckfonden BioCapital sold Amplyx Pharmaceuticals to Pfizer in 2021 after 4 years.
Lundbeckfonden BioCapital took Aura Biosciences public in 2021 after 4 years.
Lundbeckfonden BioCapital took IO Biotech public in 2021 after 6 years.
Coverage notes
1 fund tracked, 18 portfolio companies (14 active · 4 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Lundbeckfonden BioCapital has raised, with its portfolio companies. Hand-checked from public filings.
Lundbeckfonden BioCapitalActiveLife Sciences VC200914 assets4 exitsLife Sciences VC2009 · 17yr–144
Unrealized
14 held| Company | Entry |
|---|---|
| Akamis Bio Biotech · UK | 2012 |
| CytoKi Pharma Biotech · Denmark | 2019 |
| Dania Therapeutics Biotech · Denmark | 2023 |
| Enterome Biotech · France | 2012 |
| Epoqe Pharma Biotech · Denmark | 2021 |
| Folium Science AgTech · UK | 2017 |
| Kvantify Deep Tech · Denmark | 2024 |
| NMD Pharma Biotech · Denmark | 2016 |
| Notify Therapeutics Biotech · Denmark | 2021 |
| QuantumCell Biotech · Denmark | 2025 |
| SNIPR Biome Biotech · Denmark | 2019 |
| Sorriso Pharmaceuticals Biotech · US | 2021 |
| VarmX Biotech · Netherlands | 2020 |
| Vesper Bio Biotech · Denmark | 2012 |
Realized
4 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Amplyx Pharmaceuticals Biotech · US | 2017 | 2021 | Trade Sale | Pfizer | – |
| Aura Biosciences Biotech · US | 2017 | 2021 | IPO | – | – |
| IO Biotech Biotech · Denmark | 2015 | 2021 | IPO | – | – |
| Lexeo Therapeutics Biotech · US | 2021 | 2023 | IPO | – | – |
Frequently asked questions
- What investment strategy does Lundbeckfonden BioCapital focus on?
- Lundbeckfonden BioCapital focuses on VC strategies in the private equity space.
- How many portfolio companies does Lundbeckfonden BioCapital have?
- Lundbeckfonden BioCapital has 14 active portfolio companies and 4 completed exits and 1 fund tracked on GP Intel.
- Where is Lundbeckfonden BioCapital headquartered?
- Lundbeckfonden BioCapital is headquartered in Copenhagen, Denmark.
- When was Lundbeckfonden BioCapital founded?
- Lundbeckfonden BioCapital was founded in 2022.
- What sectors does Lundbeckfonden BioCapital invest in?
- Lundbeckfonden BioCapital invests across Healthcare.
- What are Lundbeckfonden BioCapital's recent exits?
- Recent realized exits by Lundbeckfonden BioCapital include: Amplyx Pharmaceuticals (2021) to Pfizer.
Similar firms
Other private equity firms tracked on GP Intel.
Denmark·€93.0B
Denmark·€700MDenmark·€500MDenmark·€300M
Denmark·€107MDenmark·€80MDenmark·€5MDenmarkDenmarkDenmark
DenmarkDenmark